Funding sources This study was funded by Galderma R&D, SNC. Funding for assistance with writing the paper was provided by Galderma Laboratories, L.P.
Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea
Article first published online: 16 JUL 2014
© 2014 British Association of Dermatologists
British Journal of Dermatology
Volume 171, Issue 1, pages 162–169, July 2014
How to Cite
Benkali, K., Leoni, M., Rony, F., Bouer, R., Fernando, A., Graeber, M. and Wagner, N. (2014), Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. British Journal of Dermatology, 171: 162–169. doi: 10.1111/bjd.12881
Conflicts of interest K.B., F.R., R.B. and N.W. are employees of Galderma R&D, Sophia Antipolis, France. M.L., A.F. and M.G. are employees of Galderma R&D, Princeton, NJ, U.S.A.
- Issue published online: 26 JUL 2014
- Article first published online: 16 JUL 2014
- Accepted manuscript online: 7 FEB 2014 12:10PM EST
- Manuscript Accepted: 1 FEB 2014
- Galderma R&D
- Galderma Laboratories
Persistent facial erythema is the most common primary pathological feature of rosacea, the only treatment for which is brimonidine tartrate (BT) gel.
To assess the relative bioavailability of topical BT gel in comparison with the ophthalmic BT solution.
A pharmacokinetic study was conducted to compare intraindividual systemic exposures after dermal application of BT gel (0·07%, 0·18% and 0·5%) under maximal use conditions in patients with moderate-to-severe facial erythema associated with rosacea, and administration of BT ophthalmic solution 0·2%.
Patients who received BT ophthalmic solution 0·2% three times a day for 1 day had a mean Cmax of 54 ± 28 pg mL−1 and a mean 0–24-h area under the curve (AUC0–24 h) of 568 ± 277 pg h mL−1. Topical application of BT gel for 29 days resulted in quantifiable systemic exposure in 22%, 48%, 71% and 79% of patients who received BT gel 0·07% twice daily, 0·18% once daily, 0·18% twice daily and 0·5% once daily, respectively. The mean Cmax values for the BT gels ranged between 13 and 25 pg mL−1, and mean AUC0–24 h values ranged between 42 and 290 pg h mL−1. Systemic exposure increased with applied dose, with no drug accumulation for the duration of treatment. The systemic exposure observed with the highest dose of BT gel (0·5% once daily) was significantly lower than the systemic levels observed for the ophthalmic solution. 0·2% apply for all the concentrations.
The systemic safety profile of BT gel may be considered better than that of the ophthalmic solution.